OGN vs OPY · P/E 3.4, rev $6.40B vs P/E 13, rev $1.43B
Organon & Co (OGN) versus Oppenheimer Holdings Inc (OPY) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Oppenheimer Holdings Inc (OPY) is a capital markets company listed on NYSE.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported OPY revenue for 2024-12-31 was $1.43B. Net income was $71.2M. Revenue was up 14.7% from 2023-12-31 to 2024-12-31. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
Not investment advice. Open the OGN and OPY stock pages for the full models.
Not investment advice.